

# Ulrike Lorch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5418727/publications.pdf>

Version: 2024-02-01

36  
papers

846  
citations

516215

16  
h-index

500791

28  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1194  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. <i>European Heart Journal</i> , 2021, 42, 178-188.	1.0	190
2	Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2008, 66, 396-404.	1.1	92
3	Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. <i>Addiction</i> , 2018, 113, 484-493.	1.7	65
4	Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1025-1036.	2.2	48
5	Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 170-179.	1.1	44
6	Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	39
7	Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1441-1447.	1.0	35
8	Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 339-348.	1.1	35
9	First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1113-1124.	1.1	33
10	Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 391-400.	1.1	31
11	A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM1 receptor inhibition. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2270-2279.	1.1	27
12	Time- and Race-Specific Haematological Reference Intervals for Healthy Volunteer Trials: A Retrospective Analysis of Pooled Data From Multiple Phase I Trials. <i>Frontiers in Pharmacology</i> , 2020, 11, 314.	1.6	24
13	Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 392-403.	1.1	22
14	The Power of Phase I Studies to Detect Clinically Relevant QTc Prolongation: A Resampling Simulation Study. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	20
15	Three steps to writing adaptive study protocols in the early phase clinical development of new medicines. <i>BMC Medical Research Methodology</i> , 2014, 14, 84.	1.4	19
16	Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 430-443.	1.0	18
17	Single Doses up to 800 mg of E-52862 Do Not Prolong the QTc Interval – A Retrospective Validation by Pharmacokinetic-Pharmacodynamic Modelling of Electrocardiography Data Utilising the Effects of a Meal on QTc to Demonstrate ECG Assay Sensitivity. <i>PLoS ONE</i> , 2015, 10, e0136369.	1.1	14
18	Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2 $\pm$ receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1839-1855.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Confirmation of the Cardiac Safety of PGF <sub>2</sub> Receptor Antagonist OBE022 in a First-In-Human Study in Healthy Subjects, Using Intensive ECG Assessments. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 889-900.	0.8	12
20	Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0163020.	1.1	10
21	Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 717-726.	0.8	10
22	Practical risk management in early phase clinical trials. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 483-496.	0.8	9
23	Kinetics of anti-SARS-CoV-2 IgG antibody levels and potential influential factors in subjects with COVID-19: A 11-month follow-up study. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 101, 115537.	0.8	8
24	Analyzing the relationship of QT interval and exposure to Nitazoxanide, a prospective candidate for influenza antiviral therapy-A formal TQT study. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 987-994.	1.0	7
25	Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 63-75.	0.6	6
26	Coadministration of the prostaglandin F <sub>2</sub> receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1516-1527.	1.1	6
27	Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QTc interval in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 296-303.	1.1	4
28	The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers. <i>Reproductive BioMedicine Online</i> , 2021, 43, 184-192.	1.1	3
29	Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	1.1	2
30	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901882108.	0.8	0
31	Efficient Design of Integrated and Adaptively Interlinked Protocols for Early-Phase Drug Development Programs. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 184-194.	0.8	0
32	Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 260-271.	0.8	0
33	Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers. <i>Scientific Reports</i> , 2021, 11, 6404.	1.6	0
34	Pharmacokinetics and Safety of the Oral Prostaglandin F <sub>2</sub> Receptor Antagonist OBE022: A First-In-Human Study in Healthy Post-Menopausal Women. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-11-7.	0.0	0
35	The pharmacokinetic interaction of the selective PGF <sub>2</sub> receptor antagonist OBE022 on co-administration with MgSO <sub>4</sub> , atosiban, nifedipine or betamethasone. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR22-4.	0.0	0
36	Diurnal and racial variance of white blood cell parameters in early phase clinical trials: a retrospective analysis of pooled data from multiple phase I trials. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, OR25-1.	0.0	0